Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Signed, informed consent * Age 4 or more years * Histologically confirmed, SCLC, (newly diagnosed or recurrent); small cell carcinoma of unknown or non-lung origin; or other types of neuroendocrine tumor OR * Histologically confirmed prostate cancer, with suspected or confirmed NEPC based upon clinical assays obtained prior to the trial OR * Histologically confirmed or suspected primary brain neoplasm * Desmoplastic small round cell tumors, osteosarcoma, Ewing's sarcoma, rabdomyosarcoma, Wilms tumors, hepatoblastomas, rhabdoid tumors and neuroblastoma patients * At least…
Interventions
- Drug89Zr-DFO-SC16.56
Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
- DrugSC16.56, Phase I, Cohort 2
7.5mg
- DrugSC16.56, Phase I, Cohort 3
22.5mg
- DrugSC16.56, Phase II
Dose for Phase II will be determined by results from Phase I.
Location
- Memorial Sloan Kettering Cancer CenterNew York, New York